GlassScriptPhysician profile
Deborah J Freeman
NPI 1639252422
$5,539.90
in general payments reported to CMS, 2019-2025
44 companies · $724 in 2025
The $724 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $999 · 2022: $1,538 · 2023: $1,096 · 2024: $1,183 · 2025: $724.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,003.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,003.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $860.56 | 2021-2025 | |
| Novo Nordisk INC | $781.72 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $761.83 | 2021-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $501.79 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Amgen INC. | $224.02 | 2021-2025 | Evenity, Otezla, Repatha |
| Pfizer INC. | $189.42 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $167.52 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $163.37 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $162.09 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $150.05 | 2021-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $130.54 | 2022-2023 | Rexulti, Nuedexta |
| Amarin Pharma, INC. | $123.68 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $108.97 | 2022 | |
| Avanir Pharmaceuticals, INC. | $107.01 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $100.14 | 2021-2023 | Ajovy |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Freeman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.